Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2007-05-01
2007-05-01
Davis, Brian J. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C562S490000, C568S929000
Reexamination Certificate
active
10986296
ABSTRACT:
A compound of the formula [I]wherein R1is optionally substituted aryl group or optionally substituted heteroaryl group; R2is optionally substituted C1-6alkyl group, C3-7cycloalkyl group and the like; R3is hydrogen atom, C1-6alkyl group, hydroxyl group and the like; R4is hydrogen atom, C1-6alkyl group and the like; R5and R6are each C1-6alkyl group and the like; R7is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2and X3are each C1-6alkylene group and the like; and X4and X5are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like.In addition, an intermediate for the compound is provided.
REFERENCES:
patent: 5336663 (1994-08-01), Wenger et al.
patent: 5684049 (1997-11-01), Van Daele et al.
patent: 5856576 (1999-01-01), Harrington et al.
patent: 0 489 670 (1992-06-01), None
patent: 0 542 685 (1993-05-01), None
patent: 0 682 007 (1995-11-01), None
patent: 0 852 224 (1998-07-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/51241 (1999-10-01), None
patent: WO 99/51569 (1999-10-01), None
patent: WO 00/09132 (2000-02-01), None
patent: WO 00/09491 (2000-02-01), None
patent: WO 00/45816 (2000-08-01), None
patent: WO 01/53254 (2001-07-01), None
patent: WO 02/07673 (2002-01-01), None
Database CAPLUS on STN, Acc. No. 1951:6812, CHEDID, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales (1950), 144, p. 675-7 (abstract).
Database CAPLUS on STN, Acc. No. 1993:39421, Kalindjian et al., WO 9211284 A1 (Jul. 9, 1992) (abstract).
Adams et al., “The Synthesis of New Bronchodilator Prodrugs,”Synthetic Communications, 1999, pp. 2419-2430, vol. 29, No. 14, Republic of South Africa.
Bect et al., “Preparation of Tetrahydrobenz[cd]indoles from 1-Tetralones,”J. Chem. Soc. Perkin Trans., 1990, pp. 689-693, United Kingdom.
Brown et al., “Cloning and Characterization of an Extracellular Ca2+-Sensing Receptor from Bovine Parathyroid,”Nature, Dec. 9, 1993, pp. 575-580, vol. 366, United States.
E.M. Brown, “Homeostatic Mechanisms Regulating Extracellular and Intracellular Calcium Metabolism,”The Parathyroids, 1994, pp. 15-54, Chapter 2, United States.
Ejersted et al., “Human Parathyroid Hormone (1-34) and (1-84) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats,”Journal of Bone and Mineral Research, 1993, pp. 1097-1101, vol. 8, No. 9, United Kingdom.
Gowen et al., “Antagonizing the Parathyroid Calcium Receptor Stimulates Parathyroid Hormone Secretion and Bone Formation in Osteopenic Rats,”The Journal of Clinical Investigation, 2000, pp. 1595-1604, vol. 105, No. 11, United States.
Ibanez et al., “New Derivatives of 2-Diphenylmethoxyethylamine with Vasodilator and Spasmolytic Activity,”Eur. J. Med. Chem., Sep.-Oct. 1977, pp. 459-462, No. 5, Spain.
J. Mizoguchi, “Effect of Intermittent Administration of hPTH Under a Hyperparathyroidism Condition in Male Rats,”Journal of Japanese Society of Bone Morphometry, 1995, pp. 33-39, vol. 5, Japan.
Mosekilde et al., The Anabolic Effects of Human Parathyroid Hormond (hPTH) on Rat Vertebral Body Mass Are also Reflected in the Quality of Bone, Assessed by Biomechanical Testing: A Comparison Study Between hPTH-(1-34) and hPTH-(1-84),Endocrinology, 1991, pp. 421-428, vol. 129, No. 1, United States.
Scutt et al., “Time-Dependent Effects of Parathyroid Hormone and Prostaglandin E2on DNA Synthesis by Periosteal Cells From Embryonic Chick Calvaria,”Calcif Tissue Int., 1994, pp. 208-215, vol. 55, United States.
C.S. Tam et al., “Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of its Resorptive Action: Differential Effects of Intermittent and Continuous Administration,” Endocrinology, 1982, pp. 506-512, vol. 110, No. 2, United States.
T. Uzawa et al., “Comparison of the Effects of Intermittent and Continuous Administration of Human Parathyroid Hormone (1-34) on Rat Bone,”Elsevier, Apr. 1995, pp. 477-484, vol. 16, No. 4, Japan.
T. J. Wronski et al., “Anabolic Effects of Parathyroid Hormone on Cortical Bone in Ovariectomized Rats,”Pergamon, 1994, pp. 51-58, vol. 15, No. 1, United States.
T. J. Wronski et al., “Parathyroid Hormone is More Effective Than Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovariectomized Rats,”Endocrinology, pp. 823-831, vol. 132, No. 2, United States.
Xu et al., “Relation Between Radioprotection and Estrogenic Effect of Nonsteroidal Estrogens,”Yao Hsueh Hsueh Pao, 1980, pp. 648-655, vol. 15, No. 11, China.
Kibe et al., “Effects of Taurine on Metabolism of Cholesterol-Bile Acid in Rabbit,”Ganryu Aminosan, 1980, pp. 183-189, vol. 3, Japan.
Padawer et al., “Combined Treatment with Radioestradiol-Lucanthone in Mouse C3HBA Mammary Adenocarcinoma and With Estradiol-Lucanthone in an Estrogen Bioassay,”Int. J. Radiat. Oncol., Biol. Phys., 1981, pp. 349-357, vol. 7, No. 3, United Kingdom.
R. Takao et al., “Effects of Human PTH(1-34) On Bone Metabolism In Rats (Fifth Report): Efficacy Of Once Weekly Administration In Normal Rats,” Japanese Journal of Bone Metabolism, 1994, p. S343, vol. 12 (Suppl.), Japan.
Chem. abstr., vol. 88, (1978), (Columbus, Ohio, USA), p. 358, col. 2, abstract No. 62084 (f)m Ibanez et al., “New derivatives of 2-diphenylmethoxylamine with vasodilator and spasmolytic activity,”Eur. J. Med. Chem. Chim. Ther., 1977, pp. 459-465 (Eng.).
Katsushima Takeo
Nakagawa Takashi
Shinagawa Yuko
Davis Brian J.
Fitzpatrick ,Cella, Harper & Scinto
Japan Tobacco Inc.
LandOfFree
Calcium receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789370